{"doi":"10.1093/oncolo/oyac244","title":"A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors","abstract":"BACKGROUND: NHS-IL12 is a first-in-class, recombinant fusion protein composed of the human monoclonal antibody NHS76 (binds exposed DNA/histones at sites of intratumoral necrosis) fused to 2 IL-12 heterodimers. The maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of NHS-IL12 monotherapy given subcutaneously (SC) every 4 weeks was previously reported. The study was expanded to include a high-exposure cohort with NHS-IL12 SC every 2 weeks (q2w). METHODS: This single-arm, phase I trial evaluated NHS-IL12 12 µg/kg SC q2w or 16.8µg/kg SC q2w in patients with metastatic solid tumors. The primary endpoint was safety. RESULTS: Using a 3+3 design, 13 patients with advanced cancer were enrolled and 12 were dose-limiting toxicity (DLT) evaluable. There was 1 DLT (Grade 3 aspartate transaminase/alanine transaminase [AST/ALT] elevation). Other grade 3 toxicities included: flu-like symptoms 1/13 (8%), decreased absolute lymphocyte count (ALC) 1/13 (8%), decreased white blood cell count (WBC) 1/13 (8%), but most adverse events reported were low grade and self-limiting grade. Fifty percent of evaluable patients (6/12) experienced stable disease (SD) with 42% (5/12) developing progressive disease (PD) at the first restaging. CONCLUSION: Biweekly NHS-IL12 was well tolerated in this small phase I study. Additional studies incorporating NHS-IL12 with other immunomodulating agents are underway. (ClinicalTrials.gov Identifier: NCT01417546).","journal":"The Oncologist","year":2023,"id":339181,"datarank":0.5880809769120143,"base_score":2.833213344056216,"endowment":2.833213344056216,"self_citation_contribution":0.42498200160843247,"citation_network_contribution":0.1630989753035818,"self_endowment_contribution":0.42498200160843247,"citer_contribution":0.1630989753035818,"corpus_percentile":null,"corpus_rank":null,"citation_count":16,"citer_count":11,"citers_with_citation_signal":8,"citers_with_endowment":8,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9554,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT01417546"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":860631,"name":"Nicholas Tschernia","orcid":"0000-0002-2389-9974","position":1,"is_corresponding":false},{"id":239941,"name":"Julius Strauss","orcid":"0000-0002-7550-4938","position":2,"is_corresponding":false},{"id":256072,"name":"Ravi A. Madan","orcid":"0000-0001-5106-8636","position":3,"is_corresponding":false},{"id":256069,"name":"Fatima Karzai","orcid":"0000-0002-3244-1332","position":4,"is_corresponding":false},{"id":256068,"name":"Marijo Bilušić","orcid":"0000-0003-1020-689X","position":5,"is_corresponding":false},{"id":256065,"name":"Jason M. Redman","orcid":"0000-0001-8200-0167","position":6,"is_corresponding":false},{"id":256066,"name":"Houssein Abdul Sater","orcid":"0000-0003-1975-3726","position":7,"is_corresponding":false},{"id":683609,"name":"Charalampos S. Floudas","orcid":"0000-0002-0020-237X","position":8,"is_corresponding":false},{"id":762302,"name":"Nicole J. Toney","orcid":"0000-0003-4181-5647","position":9,"is_corresponding":false},{"id":239940,"name":"Renee N. Donahue","orcid":"0000-0002-6828-3073","position":10,"is_corresponding":false},{"id":239939,"name":"Caroline Jochéms","orcid":"0000-0002-9000-9855","position":11,"is_corresponding":false},{"id":257287,"name":"Jennifer L. Marté","orcid":null,"position":12,"is_corresponding":false},{"id":716267,"name":"Deneise C Francis","orcid":null,"position":13,"is_corresponding":false},{"id":561112,"name":"Sheri McMahon","orcid":null,"position":14,"is_corresponding":false},{"id":257285,"name":"Elizabeth Lamping","orcid":null,"position":15,"is_corresponding":false},{"id":256067,"name":"Lisa M. Cordes","orcid":"0000-0003-3833-4084","position":16,"is_corresponding":false},{"id":239943,"name":"Jeffrey Schlom","orcid":"0000-0001-7932-4072","position":17,"is_corresponding":false},{"id":239942,"name":"James L. Gulley","orcid":"0000-0002-6569-2912","position":18,"is_corresponding":false},{"id":256063,"name":"Margaret E. Gatti‐Mays","orcid":"0000-0001-8914-2897","position":0,"is_corresponding":true}],"reference_count":22,"raw_metadata":null,"created_at":"2026-07-19T01:10:45.048445Z","pmid":"36640137","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}